Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes

Pharmacology

Volumn 54, Issue 1, 1997, Pages 49-56

  Bassleer, C ^a   Magoiteaux, J ^b   Geenen, V ^a   Malaise, M ^a  

^a Pathology Institute   (Belgium)

^b B 23 ^*  (Belgium)

Author keywords

Acetylsalicylic acid; Cartilage; Meloxicam; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROTEOGLYCAN;

ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CELL PROLIFERATION; CHONDROGENESIS; CONTROLLED STUDY; GLYCOPROTEIN SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

EID: 0031051917     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139469     Document Type: Article

References (38)

1. Hngclharclt G. Momma I, Schlege K. Ulzmann R. Schnitzler Ch: Antiinflammatory. analgesic, antipyretic and related properties of meloxi-cam, a new non-steroidal anti-in-flammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995:44:423-433.
2. Lemntel EM. Bollen W, Burgos-Vargas R. Platt P. Nissila M. Sahl-berg D. Bjdmcboc O. Baumgartner H. Valat J-P. Franchimont P. Bluhmki E. Ilanft G. Distel M: A double-blind, randomized placebo controlled trial to evaluate the efficacy and safety of meloxieam 7.5 ml and 15 mg once daily in patients with rheumatoid arthritis. J Rheumatol (in press).
3. Hosic J. Distel M. Bluhmki E: Meloxicam in osteoarthritis: A 6-month, double-blind comparison with diclofenac sodium. BrJ Rheumatol 1996; 35(suppl 1):39-43.
4. Distel M. Mueller C, Bluhmki E: Global analysis of gastrointestinal safety of a new NSAID. meloxieam. Inflammopharmacologv 1966:4:71-81.
5. Engelhardt G. Böge! R. Schnitzler Ch. Utzmann R: Meloxieam: Influence on arachidonic acid metabolism. I. In vitro findings. Biochent Pharmacol 1996:51:21-28.
6. Engelhardt G. ßögcl R. Schnitzler Ch, Utzmann R: Meloxieam: Influence on arachidonic acid metabolism. II. In vivo findings. Biochent Pharmacol 1966:51:29-38.
7. Pairel M. Engelhardt G: Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs; in Vane J, Bolting J. Betting R (cds): Improved Non-Steroid Anti-inflammatory Drugs-COX-2 Enzyme Inhibitors. London. Kluwer Academic Publishers, 1996. pp 103-119.
8. Churchill I. Graham AG. Shill C-K. Pauletti D. Farina PR. Grob PM: Selective inhibition of human cyclo-oxygenase-2 by meloxieam. Inflam-mopharmacologv 1996:4:125-135.
9. Palmoski MJ. Colycr R. Brandt KD: Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritis cartilage. Arthritis Rheum 1980:23:83-91.
10. Palmoski MJ. Brandi KD: Effects of some nonsteroidal antiinflammatory drugs on proteoglycan metabolism and organisation in canine articular cartilage. Arthritis Rheum 1980;23:1010-1020.
11. Fujii K. Tajiri K. Kajiwara T, Tanaka T. Murota K: Effects of NSAID on collagen and proteoglycan synthesis of cultured chondrocytes. J Rheumatol 1989;16:19-28.
12. Mohr W, Kirkpatrick CJ, Wildfeuer A, Leitold M: Effects of piroxicam on structure and function of joint cartilage. Inflammation 1984:8 (suppl 5): 139-154.
13. Brandt KD: Effects of nonsteroidal antiinflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med 1987;83(suppl 5A): 29-34.
14. Bassleer C. Gvsen P. Foidan JM. Bassleer R, Franchimont P: Human chondrocytes in tridimensional culture in vitro. Cell Dev Biol 1986:22: 113-119.
15. Degner F. Heinzel G, Busch U: Transsynovial kinetics of meloxi-cam (abstract). Scand J Rheumatol 1994;23(suppl 98):121.
16. Tiirck D. Busch U, Heinzel G. Narjes H: Clinical pharmacokinetics of mcloxicam. Eur.J Rheumatol Inflamm 1966 (in press).
17. Soren A: Kinetics of salicylates in blood and joint fluid. Eur J Clin Pharmacol 1979;16:279-285.
18. Levy G. Diacomini KM: Rational aspirin dosage regimens. Curr Ther 1979:20:113.
19. Gysen P. Franchimont P: Radioimmunoassay of proteoglycans. J immunoassay 1984;5:221-243.
20. Oegema TR. Hascall VC. Dreiwat-kowski D: Isolation and characterisation of proteoglycan from the swarm rat chondrosarcoma. J Biol Chcm 1975;250:6151-6159.
21. Hcnrotin Y. Bassleer C. Nusgens B. Franchimont P: Radioimmunoassay of human type II collagen. J Immunoassay 1990;11:555-579.
22. Labarca C. Paigcn K: A simple, rapid and sensitive DNA assay procedure. Anal Biochcm 1980; 102:344-352.
23. Bassleer C. Bassleer R, Franchimont P: DNA synthesis in human chondrocytes cultivated in clusters. Eur Arch Biol 1991:102:1-5.
24. Serteyn D. Deby-Dupont G. Pince-mail J. Mottart E. Phillipart C. Lamy M: Equine post-anaesthetic myositis: Thromboxane, prostacyclin and prostaglandin E; production. Vet Res Commun 1988:12: 219-226.
25. Dunnett CW: A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc 1955:50:1096-1121.
26. Brandt KD, Slowman-Kovacs S: Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. Clin Orthop 1983:213:84-91.
27. De Vries BJ. Van Den Berg WB. Van De Putte VB: Salicylate induced depletion of endogenous inorganic sulphate. Arthritis Rheum 1985:28:922-929.
28. Palmoski MJ. Brandt KD: Effects of salicylate and indomethacin on GAG and PGE2 synthesis in intact canine knee cartilage in vivo. Arthritis Rheum 1984:27:398-403.
29. Mohr W: Chondro-neurality of mcl-oxicani in spontaneously occurring osteoarthritis in rats and mice. Congr Degenerative Inflamm Processes Joint. Bari, Scptcmbcr-October 1994.
30. Kalbhcn DA: Einflüsse anti-rhcumatischcr Pharmaka auf den Gclcnkknorpcl. Aktucl Rheumatol 1982:7:211-217.
31. Ronningen H, Langeland N: Indomethacin treatment in osteoarthritis of the hip joints. Does the treatment interfere with the natural course of the disease? Acta Orthop Scand 1979:50:169-174.
32. Herman JH, Appel AM. Khosla RC. Hess EV: The in vitro effect of select classes of non-steroidal anti-inflammatory drugs on normal cartilage metabolism. J Rheumatol 1986:13: 1014-1018.
33. Verbruggen G, Vcys EM. Malfait AM. Cochez P. Schattcnman L, Wienie N. Heyncn G. Broddelez C: Proteoglycan metabolism in tissue cultured human articular cartilage. Influence of piroxicam. J Rheumatol 1989:16:355-362.
34. Rainsford KD. Ying C. Smith F: Comparative effects of mcloxicam on cartilage-synovial components of joint injury in vitro (poster). 2nd Int Congr Osteoarthritis Res Soc. Orlando, December 1994.
35. Rashad S. Revell P. Hemingway A, Low F. Rainsford K. Walker F: Effects of nonsteroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; vol ii:519-522.
36. Rainsford KD. Davis A, Mundy L, Ginsburg I: Comparative effects of azapropazone on cellular events at inflamed sites. Influence on joint pathology in arthritic rats, leucocyte superoxide and ecosanoid production. platelet aggregations, synthesis of cartilage proteoglycans, synovial production and actions of interleukin-1 in cartilage resorption correlated with drug uptake into cartilage in vitro. J Pharm Pharmacol 1989: 41:322-330.
37. Rainsford KD. Rashad SY. Revell PA. Low FM. Hemingway AP, Walker FS. Johnson D. Stetsko P. Ying C. Smith F: Effects of NSAlDs on cartilage proteoglycan metabolism in relation to joint deterioration on osteoarthritis; in Balini G, Gomar L. Hodinka L (eds): Rheumatology State of the Art. Amsterdam. Elsevier. 1992. pp 177-183.
38. Knott I, Dieu M. Burton M. Hou-bion A. Remade J, Raes M: Induction of cyclooxygenase by interlcu-kin-1: Comparative study between human synovial cells and chondrocytes. J Rheumatol 1994:21:462-466.